1.Clinical applications of interleukin-2.
Korean Journal of Medicine 1999;57(4):453-458
No abstract available.
Interleukin-2*
2.The in vitro distribution of 99mTc-phytate IL-2 complex on selective splenic arterial injection.
Seok Kil SEON ; Hee Jung LEE ; Soo Sang SOHN
Korean Journal of Nuclear Medicine 1992;26(1):124-126
No abstract available.
Interleukin-2*
3.Modification of Immune Response by Cold Stress in Mice.
Young Min PARK ; Yang Hyo OH ; Young Ran SEONG ; Jung Cheol LEE ; Seol Hyang BAEK
Korean Journal of Immunology 1997;19(4):437-446
No abstract available.
Animals
;
Interleukin-2
;
Mice*
4.A Study of Interleukin-2 Activity in Behçet's Syndrome.
Eun So LEE ; Yoo Deuk LEE ; Seung Hun LEE ; Dong Sik BANG ; Sung Nack LEE
Annals of Dermatology 1991;3(1):5-11
This study was undertaken to investigate immunological mechanisms in Behçet's syndrome, a function considered important in the pathogenesis of the disease. The activity of interleukin-2 (IL-2), which is believed, to play a central role in the regulation of both cell-mediated and humoral T cell-dependent immune responses, measured in 46 patients with complete, in-complete or suspected Behçet's syndrome. The results were as follows: 1 . There was no significant difference between the average IL-2 activity of patients and control group. 2. For each clinical subtype of Behçet's syndrome, IL-2 activity was lower than the control value, but the difference was not statistically significant. 3. In mucocutaneous and ocular types, the greater the clinical symptoms, the lower the value of IL-2 activity. However, the decrease of IL-2 activity was not statistically significant. In conclusion, IL-2 activity of phytohemaggludnin (PHIS-stimulated peripheral blood lymphocytes in patients with Behçet's syndrome was not significantly decreased compared to control population.
Humans
;
Interleukin-2*
;
Lymphocytes
5.Levels od serum soluble interleukin-2 receptor in patients with burn.
Yu Jin LEE ; Jong Ryung LEE ; Jae Sung HA ; Koun Soo CHUN ; Hee Sung LEE ; Kwang Jin BAEK
Journal of the Korean Society of Plastic and Reconstructive Surgeons 1991;18(2):222-230
No abstract available.
Burns*
;
Humans
;
Interleukin-2*
6.Evaluation of serum levels of soluble interleukin-2 receptor in patients with acute leukemia.
Si Chan KIM ; Yoo Hong MIN ; Sun Ju LEE ; Jee Sook HAHN ; Yun Woong KO
Korean Journal of Hematology 1993;28(2):299-305
No abstract available.
Humans
;
Interleukin-2*
;
Leukemia*
7.Effect of ethanol feeding on production of IL-2 and IL-6, and otherparameters of immunocompatency in rats.
Tai You HA ; Byung Sook PARK ; Hee Sung HWANG
Korean Journal of Immunology 1991;13(1):17-31
No abstract available.
Animals
;
Ethanol*
;
Interleukin-2*
;
Interleukin-6*
;
Rats*
8.The soluble interleukin 2 receptor levels in Kawasaki disease.
Journal of the Korean Pediatric Society 1992;35(12):1657-1666
No abstract available.
Interleukin-2*
;
Interleukins*
;
Mucocutaneous Lymph Node Syndrome*
;
Receptors, Interleukin-2*
9.Effect of electric shock stress and psychological stress of conflict stimulation on interleukin-2 production and lymphokine-activatedkiller cell cytotoxicity.
Dong Rag CHOI ; Jung Mogg KIM ; Yong CHOI ; Yang Ja CHO
Korean Journal of Immunology 1991;13(2):151-162
No abstract available.
Interleukin-2*
;
Shock*
;
Stress, Psychological*
10.Serum Anti-Acetylcholine Receptor Antibody, Interleukin-2 and Soluble Interleukin-2 Receptor Level in Myasthenia Gvavis.
Jeong Geun LIM ; Jun Hyung PARK ; Young Soo YOU ; Sang Do YI ; Young Choon PARK
Journal of the Korean Neurological Association 1996;14(3):773-780
Objective/BACKGROUND: Serum levels of anti-acetylcholine receptor antibody (AChR-Ab), interleukin-2 (IL-2) and soluble interleukin-2 receptor (sIL-2R) may represent markers of disease severity in myasthenia gravis (MG). This study was performed to evaluate the correlations between disease severity and immunological parameters such as serum AChR-Ab, IL-2 and sIL-2R level and between each immunological parameters. METHODS: Serum levels of AChR-Ab, IL-2 and sIL-2R were measured in 30 MG patients and in 22 healthy controls. Results : Serum levels of AChR-Ab and sIL-2R were higher in MG than in healthy controls (p<0,01). The occurrence of IL-2 positive serum samples was 46.7% in MG but none in controls. There were no significant correlations between disease severity and immunological parameters and between each immunological parameters. Conclusions : Serum IL-2 and sIL-2R levels may not represent markers of disease severity in MG, In order to further document the correlation between each parameters, follow-up of individual patients with serial serum samplings may be necessary.
Humans
;
Interleukin-2*
;
Myasthenia Gravis
Result Analysis
Print
Save
E-mail